REGENXBIO (RGNX) Stock Soars On Encouraging Trial Efficacy Data
After receiving favorable data regarding the efficacy of its clinical research, REGENXBIO Inc. (NASDAQ: RGNX) witnessed a significant gain in value, with its shares soaring by 15.17% to $24.60. RGNX today reported early findings from the Phase I/II AFFINITY DUCHENNE research of RGX-202, a potential treatment for Duchenne muscular dystrophy (Duchenne), in children ages 4 […]
Regenxbio [RGNX] Unchanged to Market Perform at SVB Leerink
SVB Leerink maintained its Regenxbio [RGNX] rating to the equivalent of Market Perform but changed the price target to $37 from $34, in a research note dated 2021-01-06. That figure represents around a -17.61% premium from where the company’s shares closed on Tuesday. In addition, RBC Capital Mkts launched coverage on May 13, 2020. The […]